This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by McDevitt, L. M. Search for Related Content Social Bookmarking                         What's this?

Immunosuppressive Agents on the Horizon

Pharmacy Practice, Massachusetts, College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115lisa.mcdevitt{at}mcp.edu

The evolution of immunosuppression in organ transplantation has resulted in decreasing rates of rejection and improved allograft survival. The current successes, however, comes at the price of intense drug monitoring, frequent adverse affects, and long-term toxicity. New immunosuppressive agents offer the hope for decreased toxicity and improved long-term results. This article highlights those novel agents that are currently in late-stage clinical studies including new calcineurin inhibitor analogs and formulations, mycophenolate acid sodium, everolimus, FK-778, FTY720, and various monoclonal antibodies. The diverse mechanisms of action of these agents, coupled with promising efficacy and adverse effect profiles, may land each of them a unique niche for immunosuppression in organ transplantation.

Key Words: Immunosuppression • novel agents • transplantation

Journal of Pharmacy Practice, Vol. 16, No. 6, 434-441 (2003)
DOI: 10.1177/0897190003259384


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?